XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Collaborative Arrangements - Schedule of Transactions (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales $ 12,080 $ 12,057  
Cost of sales 3,670 3,312  
Selling, general and administrative 2,633 2,555  
Research and development 2,465 2,209  
Payables, current 26,361   $ 27,327
Other current assets | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables from Bayer included in Other current assets 236   215
Other current assets | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables from Bayer included in Other current assets 153   157
Other current assets | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables from Bayer included in Other current assets 68   65
Accounts payable and accrued liabilities | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables, current 417   423
Accounts payable and accrued liabilities | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables, current 300   335
Other Noncurrent Liabilities | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables to Bayer included in Other Noncurrent Liabilities 300   600
Other Noncurrent Liabilities | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables to Bayer included in Other Noncurrent Liabilities 400   $ 0
Revenue | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 233 145  
Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Lynparza (1)      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 228 145  
Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Koselugo      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 5 0  
Revenue | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 130 128  
Revenue | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 74 53  
Collaborative Arrangement, Sales, Net 55 56  
Sales 129 109  
Cost of sales | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 42 28  
Cost of sales | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 47 35  
Cost of sales | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 189 28  
Amortization of intangible assets 153    
Selling, general and administrative | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 40 33  
Selling, general and administrative | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 23 11  
Selling, general and administrative | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 32 15  
Research and development | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development 29 36  
Research and development | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development 64 64  
Research and development | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development $ 7 $ 25